Verteporfin — Safety, Research, Risks & Legal Status

Not medical advice. Verteporfin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Visudyne; benzoporphyrin derivative monoacid ring A (BPD-MA)
Category	Research Chemical
FDA approval year	2000 (NDA 21-119; ophthalmic PDT for wet AMD)
Activation wavelength	693 nm red light (PDT mechanism only)
Formulation	Liposomal IV injection; complex lipid carrier required for stability
YAP mechanism p53 dependency	Preclinical evidence indicates YAP inhibitory effect requires intact p53; p53-mutant tumors may not respond
Current manufacturer	Bausch Health US LLC / Bausch & Lomb (NDC 0187-5600-15)
Oncology trial status	No completed Phase II/III human oncology trials as of mid-2026; active early-stage scar trial (SCARFREE-001)
US legal status	FDA-approved (NDA 21-119, April 2000) for ophthalmic photodynamic therapy (wet AMD, pathologic myopia, presumed ocular histoplasmosis syndrome with subfoveal choroidal neovascularization). All oncology and non-ophthalmic uses are off-label and investigational. Not approved for human consumption outside its labeled ophthalmic indication. Research use in cancer models is preclinical.

What is Verteporfin?

Verteporfin is an FDA-approved benzoporphyrin-derivative photosensitizing agent formulated as a liposomal injection for ophthalmic photodynamic therapy (PDT). It selectively accumulates in abnormal choroidal vasculature; activation by 693 nm red light generates reactive oxygen species that occlude leaking vessels. Separately, verteporfin has attracted preclinical research interest as a small-molecule inhibitor of the YAP/Hippo pathway, a mechanotransduction signaling axis implicated in tumor proliferation, therapy resistance, and cancer stem cell maintenance. This second mechanism is independent of light activation and operates through cytoplasmic sequestration of YAP protein. As of mid-2026, the YAP-inhibition application remains preclinical or in very early-stage trials; no completed Phase II or Phase III human oncology data have been published.

How it works

Two distinct mechanisms operate in parallel. First, the approved PDT mechanism: verteporfin (liposomal formulation) is administered intravenously and preferentially localizes to rapidly proliferating endothelial cells in choroidal neovascular membranes. Illumination at 693 nm activates the porphyrin chromophore, transferring energy to molecular oxygen to produce singlet oxygen and reactive oxygen species. Endothelial oxidative damage causes thrombosis and occlusion of the abnormal vessels with relative sparing of overlying retinal tissue. Second, the investigational YAP-inhibition mechanism: verteporfin elevates cytoplasmic levels of the 14-3-3σ chaperone protein, which sequesters Yes-associated protein (YAP) outside the nucleus, promotes its ubiquitin-proteasomal degradation, and disrupts the YAP-TEAD transcriptional complex. This effect has been shown in preclinical models to be p53-dependent - tumors harboring p53 loss-of-function mutations may have attenuated responses. Because this mechanism does not require light activation, it is being explored systemically in oncology contexts.

Background & history

Verteporfin was co-developed by QLT PhotoTherapeutics Inc. (Seattle, WA) and CIBA Vision (Duluth, GA) through the 1990s. FDA approval was granted in April 2000 under NDA 21-119 for wet AMD, marking the first approved PDT agent for ocular neovascularization. Novartis held commercialization rights for the liposomal formulation at approval. The compound was subsequently acquired by Bausch Health US LLC / Bausch & Lomb, which continues commercialization. The ophthalmic indication has over 26 years of post-market safety data. Academic interest in YAP inhibition emerged after a 2015 mechanistic study (PMC4759394) identified verteporfin as a small-molecule YAP disruptor independent of its photodynamic function, triggering a wave of preclinical cancer biology research that accelerated through 2020-2025. As of 2026, repurposing for oncology and scar prevention (SCARFREE-001, NCT07488988) remains in early clinical investigation.

What the research says

The ophthalmic evidence base is mature and well-supported: multiple randomized controlled trials and over two decades of clinical use established efficacy for subfoveal choroidal neovascularization in AMD and related conditions. The YAP-inhibition research base is extensive in preclinical models but thin in humans. Published in-vitro and animal studies have examined verteporfin against hepatocellular carcinoma, endometrial carcinoma, head and neck squamous cell carcinoma, mesothelioma, glioma, soft-tissue sarcomas, and bladder cancer, generally showing suppression of proliferation, cancer stem cell phenotypes, and (in some models) enhancement of radiosensitivity. A 2024 study demonstrated mechanotransduction blocking in fibroblasts relevant to fibrosis and scar formation. A scar prevention trial (SCARFREE-001) is active as of 2026. No completed Phase II or Phase III human oncology trials have been published; the cancer repurposing literature is largely in-vitro or rodent-model work. The p53-dependence of the YAP mechanism is a noted limitation that may constrain efficacy in the mutation-heavy cancers where YAP pathway upregulation is most common.

Reported effects

Photodynamic occlusion of choroidal neovascular membranes in ophthalmic PDT (approved, clinically established)
YAP/TEAD transcriptional complex disruption via 14-3-3σ-mediated cytoplasmic sequestration (preclinical)
Suppression of cancer stem cell phenotypes in mesothelioma, hepatocellular carcinoma, and glioma models (animal and in-vitro only)
Potential radiosensitization in preclinical head and neck cancer models (biorXiv preprint, not peer-reviewed final)
Progestin resistance reversal via YAP/TAZ-PI3K-Akt pathway in endometrial cancer models (preclinical)
Inhibition of cGAS-STING pathway activity in hepatocellular carcinoma models (preclinical, 2025)
Mechanotransduction blocking in fibroblasts relevant to fibrosis (preclinical, 2024)

Dosing & administration (informational)

In its approved ophthalmic indication, the labeled dose is 6 mg/m² body surface area administered as a 10-minute IV infusion, followed by laser activation at 693 nm at 15 minutes post-infusion. This information is drawn from the FDA-approved labeling and is provided for reference only. Dosing in preclinical cancer research models varies widely across studies and is not translatable to human use. No human oncology dosing protocol has been established. This is not a dosing recommendation; consult a licensed clinician for any therapeutic questions.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Well-characterized safety profile from ophthalmic PDT use over 26 years at approved doses
Injection-site reactions reported in approximately 13% of patients in ophthalmic trials
Photosensitivity reactions in approximately 2.4% - patients must avoid direct sunlight and bright indoor light for 5 days post-infusion
Serious but rare reactions include vaso-vagal episodes, syncope, acute severe decrease in vision, chest pain, and acute respiratory distress
Hypersensitivity reactions have been reported
YAP-inhibition-context systemic dosing and its safety profile have not been characterized in human trials; extrapolation from ophthalmic dosing is not valid
P53-mutant tumor contexts may yield altered pharmacodynamic responses; clinical implications unknown

Drug & supplement interactions

I
n
o
p
h
t
h
a
l
m
i
c
P
D
T
u
s
e
,
c
o
n
c
o
m
i
t
a
n
t
p
h
o
t
o
s
e
n
s
i
t
i
z
i
n
g
a
g
e
n
t
s
(
t
e
t
r
a
c
y
c
l
i
n
e
s
,
s
u
l
f
o
n
a
m
i
d
e
s
,
p
h
e
n
o
t
h
i
a
z
i
n
e
s
,
s
u
l
f
o
n
y
l
u
r
e
a
s
,
t
h
i
a
z
i
d
e
d
i
u
r
e
t
i
c
s
,
g
r
i
s
e
o
f
u
l
v
i
n
)
m
a
y
i
n
c
r
e
a
s
e
p
h
o
t
o
s
e
n
s
i
t
i
v
i
t
y
r
i
s
k
.
C
a
l
c
i
u
m
c
h
a
n
n
e
l
b
l
o
c
k
e
r
s
,
p
o
l
y
m
y
x
i
n
B
,
a
n
d
r
a
d
i
a
t
i
o
n
t
h
e
r
a
p
y
h
a
v
e
b
e
e
n
n
o
t
e
d
i
n
l
a
b
e
l
i
n
g
a
s
p
o
t
e
n
t
i
a
l
l
y
e
n
h
a
n
c
i
n
g
v
a
s
c
u
l
a
r
u
p
t
a
k
e
o
r
r
e
s
p
o
n
s
e
.
A
n
t
i
o
x
i
d
a
n
t
s
o
r
c
o
m
p
o
u
n
d
s
t
h
a
t
q
u
e
n
c
h
s
i
n
g
l
e
t
o
x
y
g
e
n
m
a
y
t
h
e
o
r
e
t
i
c
a
l
l
y
r
e
d
u
c
e
P
D
T
e
f
f
i
c
a
c
y
.
F
o
r
t
h
e
Y
A
P
-
i
n
h
i
b
i
t
i
o
n
m
e
c
h
a
n
i
s
m
i
n
p
r
e
c
l
i
n
i
c
a
l
c
o
n
t
e
x
t
s
,
n
o
s
y
s
t
e
m
a
t
i
c
h
u
m
a
n
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
e
x
i
s
t
.

Who should avoid it

Self-administration outside a supervised clinical setting - this is an IV pharmaceutical requiring controlled light-activation protocols
Use in individuals with porphyria (contraindicated per FDA labeling)
Prolonged sunlight or bright indoor light exposure within 5 days of infusion
Extrapolating ophthalmic PDT safety data to systemic oncology dosing - the exposure profiles differ
Assuming efficacy against p53-mutant cancers based on available preclinical data - the mechanistic evidence suggests reduced YAP inhibition in that context

How it is commonly combined

No established stacking protocols exist for verteporfin's investigational YAP-inhibition use. In preclinical models, combination with radiotherapy has been explored (radiosensitization context, preprint evidence only). Some preclinical work has combined verteporfin with standard-of-care chemotherapeutics in cancer models. No human combination data for oncology use are available. In its approved ophthalmic context, it is used as a standalone PDT agent.

Legal & regulatory. FDA-approved (NDA 21-119, April 2000) for ophthalmic photodynamic therapy (wet AMD, pathologic myopia, presumed ocular histoplasmosis syndrome with subfoveal choroidal neovascularization). All oncology and non-ophthalmic uses are off-label and investigational. Not approved for human consumption outside its labeled ophthalmic indication. Research use in cancer models is preclinical.

Quality & harm reduction

V
e
r
t
e
p
o
r
f
i
n
(
V
i
s
u
d
y
n
e
)
i
s
a
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
I
V
a
g
e
n
t
m
a
n
u
f
a
c
t
u
r
e
d
u
n
d
e
r
G
M
P
b
y
B
a
u
s
c
h
&
L
o
m
b
f
o
r
i
t
s
a
p
p
r
o
v
e
d
o
p
h
t
h
a
l
m
i
c
i
n
d
i
c
a
t
i
o
n
.
I
t
i
s
n
o
t
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
a
s
a
r
e
s
e
a
r
c
h
c
h
e
m
i
c
a
l
o
r
s
u
p
p
l
e
m
e
n
t
.
A
n
y
m
a
t
e
r
i
a
l
o
b
t
a
i
n
e
d
o
u
t
s
i
d
e
l
i
c
e
n
s
e
d
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
u
p
p
l
y
c
h
a
i
n
s
c
a
r
r
i
e
s
u
n
k
n
o
w
n
p
u
r
i
t
y
,
p
o
t
e
n
c
y
,
a
n
d
s
t
e
r
i
l
i
t
y
.
T
h
e
l
i
p
o
s
o
m
a
l
f
o
r
m
u
l
a
t
i
o
n
i
s
c
o
m
p
l
e
x
a
n
d
s
t
a
b
i
l
i
t
y
-
d
e
p
e
n
d
e
n
t
;
c
o
m
p
o
u
n
d
e
d
o
r
g
r
a
y
-
m
a
r
k
e
t
p
r
e
p
a
r
a
t
i
o
n
s
c
a
n
n
o
t
b
e
a
s
s
u
m
e
d
e
q
u
i
v
a
l
e
n
t
.

Safer, legal alternative we recommend

Creatine Supreme. For a legal, proven performance-support option toward the same goal, creatine monohydrate has the deepest evidence base - ours ships from the Peptropix line.

See our recommended pick

Find Verteporfin →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is verteporfin approved for cancer treatment?

No. Verteporfin is FDA-approved only for ophthalmic photodynamic therapy in wet AMD and related conditions. Its use as a YAP inhibitor in oncology is investigational and supported only by preclinical (in-vitro and animal) data as of mid-2026. No Phase II or Phase III human oncology trials have been completed.

Does verteporfin require light activation to inhibit YAP?

No. The YAP-inhibition mechanism operates independently of light activation. It involves upregulation of the 14-3-3σ chaperone protein, which sequesters YAP in the cytoplasm and promotes its degradation. However, this mechanism has only been characterized in preclinical models; its behavior in humans outside the ophthalmic PDT context is not established.

What is the significance of p53 status for verteporfin's YAP inhibition?

Preclinical mechanistic studies indicate that verteporfin's YAP inhibitory effect is p53-dependent. Tumors with p53 loss-of-function mutations - which are common in many cancers where YAP pathway upregulation is also prevalent - may have substantially reduced responses. This is an important caveat when interpreting preclinical efficacy data and would need to be addressed in any clinical trial design.

Can I obtain and use verteporfin for off-label purposes?

Verteporfin is a prescription IV pharmaceutical, not a supplement or research chemical available for consumer purchase. It is not appropriate or safe for self-administration. Its ophthalmic use requires clinical infrastructure including IV administration, precise dosimetry, and controlled light exposure protocols. Anyone with questions about its investigational oncology applications should consult an oncologist or participate in a registered clinical trial.

What dose is used in clinical practice?

The FDA-approved ophthalmic dose is 6 mg/m² body surface area given as a 10-minute IV infusion, followed by laser activation at 15 minutes post-infusion. This is provided as reference information from the approved labeling only. No established human dose exists for oncology or other investigational uses. This is not a dosing protocol - consult a licensed clinician.

Are there human trials of verteporfin for cancer currently underway?

As of mid-2026, ClinicalTrials.gov lists approximately 8-12 entries for verteporfin; most are historical AMD trials. The SCARFREE-001 trial (NCT07488988) is an active early-stage study investigating scar prevention. Oncology-focused human trials remain limited; the bulk of the cancer research evidence base is preclinical. Searching ClinicalTrials.gov for 'Verteporfin' will return the current registered study list.

References & further reading

PubMed: "verteporfin" AND ("YAP" OR "Hippo pathway") - retrieves 100+ results; mechanistic foundation paper PMC4759394 (2015)
PubMed: verteporfin cancer 2024 - retrieves recent preclinical applications including hepatocellular carcinoma, glioma, and fibrosis models
ClinicalTrials.gov: search Verteporfin - returns approximately 8-12 entries; active scar prevention trial SCARFREE-001 (NCT07488988)
FDA Drug Approval Package NDA 21-119 / Visudyne (accessdata.fda.gov) - approved labeling, clinical trial summaries, safety data
PubMed: verteporfin mesothelioma OR "head and neck" OR glioma - retrieves tumor-type-specific preclinical studies 2020-2025